The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NKTX | -40.06% | -93.07% | -41.34% | -96% |
| S&P | +12.65% | +91.73% | +13.89% | +111% |
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$2.33M | -3.1% |
| Market Cap | $117.79M | -71.7% |
| Market Cap / Employee | $1.07M | 0.0% |
| Employees | 110 | 0.0% |
| Net Income | -$22.98M | 8.1% |
| EBITDA | -$24.86M | 12.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $53.41M | -55.6% |
| Accounts Receivable | $0.20M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $71.63M | -10.5% |
| Short Term Debt | $6.91M | 24.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -21.80% | 0.2% |
| Return On Invested Capital | -28.33% | 6.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18.89M | 22.1% |
| Operating Free Cash Flow | -$18.75M | 14.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.74 | 0.41 | 0.32 | 0.31 | -64.62% |
| Price to Tangible Book Value | 0.74 | 0.41 | 0.32 | 0.31 | -64.62% |
| Enterprise Value to EBITDA | -4.29 | 0.13 | 1.48 | 3.55 | -151.83% |
| Return on Equity | -30.4% | -31.9% | -26.1% | -26.9% | -3.72% |
| Total Debt | $85.45M | $80.27M | $78.91M | $78.54M | -8.22% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
